Tetrahedral Antibody Architecture for Simultaneous Multi-Target Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody engineering efforts struggle to simultaneously engage multiple targets due to the planar configuration of binding domains, which limits the ability to bind multiple antigens effectively.
Innovation Solution
Development of tetrahedral and octahedral antibodies with non-peptidyl linkages and peptide bonds or linkers to connect Fab and Fc domains, allowing for multiple binding sites through dimerizing or trimerizing polypeptides that are not immunoglobulin polypeptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional planar antibody structure is used, then structural simplicity and ease of manufacture are maintained, but the ability to simultaneously engage multiple targets is limited
Solution Approach 1:
The patent transitions from a two-dimensional planar antibody structure to a three-dimensional tetrahedral configuration. This dimensional change allows binding domains to be positioned at the vertices of a tetrahedron, enabling simultaneous engagement of multiple targets in three-dimensional space that cannot be achieved with planar geometry alone.
Solution Approach 2:
The antibody is divided into multiple binding domains (Fab and Fc regions) that are independently positioned at different vertices of the tetrahedron. This segmentation allows each domain to independently bind to different targets, with the overall structure organized as four separate domains connected through engineered linkages rather than a single continuous polypeptide chain.
2Adaptability or versatility
If tetrahedral antibody structure with non-peptidyl linkages is implemented, then multi-target engagement capability is enhanced, but manufacturing complexity and production difficulty increase
Solution Approach 1:
Non-peptidyl linkages such as disulfide bonds, PEG spacers, or other chemical connectors serve as intermediaries to join the binding domains at the tetrahedral vertices. These intermediary linkages provide flexible connection points that maintain the three-dimensional structure while being amenable to chemical synthesis and purification processes.
Solution Approach 2:
The antibody construct combines traditional immunoglobulin domains with non-proteinaceous linkages (PEG chains, disulfide bridges, or other synthetic connectors) to create a composite molecular structure. This composite approach allows integration of rigid binding domains with flexible, chemically-tunable linkers that facilitate both structure formation and manufacturing.
3Adaptability or versatility
If traditional Y-shaped antibody structure is used, then structural stability and simplicity are maintained, but functional versatility for simultaneous multi-target binding is reduced
Solution Approach 1:
The patent replaces the traditional two-dimensional Y-shaped structure with a three-dimensional tetrahedral arrangement where binding domains are positioned at vertices separated in three-dimensional space. This spatial reconfiguration maintains structural integrity through the tetrahedral geometry while enabling simultaneous binding to multiple targets that would be inaccessible from a planar configuration.
Solution Approach 2:
The tetrahedral structure introduces curved and three-dimensional spatial relationships between binding domains, replacing the flat planar geometry of conventional antibodies. This spherical/three-dimensional arrangement allows binding sites to be oriented in multiple directions in space, enhancing the ability to engage targets with different spatial orientations while maintaining overall structural coherence.
Data Source
AI summary
This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.